Northwest Bioth Cmn (NWBO): Price and Financial Metrics

Northwest Bioth Cmn (NWBO): $0.71

0.00 (0.00%)

POWR Rating

Component Grades








Add NWBO to Watchlist
Sign Up

Industry: Biotech




#227 of 382

in industry

NWBO Price/Volume Stats

Current price $0.71 52-week high $1.27
Prev. close $0.71 52-week low $0.45
Day low $0.70 Volume 792,202
Day high $0.73 Avg. volume 1,703,399
50-day MA $0.58 Dividend yield N/A
200-day MA $0.70 Market Cap 773.92M

NWBO Stock Price Chart Interactive Chart >


  • NWBO scores best on the Growth dimension, with a Growth rank ahead of 70.09% of US stocks.
  • The strongest trend for NWBO is in Quality, which has been heading down over the past 179 days.
  • NWBO ranks lowest in Quality; there it ranks in the 12th percentile.

NWBO Stock Summary

  • NORTHWEST BIOTHERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.58% of US listed stocks.
  • With a price/sales ratio of 308.92, NORTHWEST BIOTHERAPEUTICS INC has a higher such ratio than 98.74% of stocks in our set.
  • NWBO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 6.33% of US stocks.
  • If you're looking for stocks that are quantitatively similar to NORTHWEST BIOTHERAPEUTICS INC, a group of peers worth examining would be HLTH, CLXT, AIP, PACB, and TGTX.
  • Visit NWBO's SEC page to see the company's official filings. To visit the company's web site, go to

NWBO Valuation Summary

  • In comparison to the median Healthcare stock, NWBO's price/sales ratio is 5819.61% higher, now standing at 301.9.
  • NWBO's price/sales ratio has moved up 251.2 over the prior 243 months.

Below are key valuation metrics over time for NWBO.

Stock Date P/S P/B P/E EV/EBIT
NWBO 2023-05-23 301.9 -11.6 -6.4 -7.0
NWBO 2023-05-22 301.9 -11.6 -6.4 -7.0
NWBO 2023-05-19 304.4 -11.7 -6.5 -7.1
NWBO 2023-05-18 291.8 -11.3 -6.2 -6.8
NWBO 2023-05-17 301.4 -11.6 -6.4 -7.0
NWBO 2023-05-16 306.9 -11.8 -6.5 -7.1

NWBO Growth Metrics

    The 2 year cash and equivalents growth rate now stands at 811.39%.
  • The 5 year net income to common stockholders growth rate now stands at 103.65%.
  • Its 4 year price growth rate is now at 137.5%.
Over the past 15 months, NWBO's revenue has gone down $288,000.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.086 -55.172 56.586
2022-06-30 1.23 -46.067 134.957
2022-03-31 1.169 -38.018 169.035
2021-12-31 1.005 -38.299 179.126
2021-09-30 1.508 -37.256 -234.493
2021-06-30 1.374 -38.265 -474.108

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NWBO has a Quality Grade of C, ranking ahead of 27.35% of graded US stocks.
  • NWBO's asset turnover comes in at 0.045 -- ranking 328th of 682 Pharmaceutical Products stocks.
  • EDSA, BLCM, and GLYC are the stocks whose asset turnover ratios are most correlated with NWBO.

The table below shows NWBO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.045 1 1.610
2021-03-31 0.036 1 2.337
2020-12-31 0.061 1 3.470
2020-09-30 0.112 1 3.430
2020-06-30 0.190 1 1.815
2020-03-31 0.245 1 -0.306

Northwest Bioth Cmn (NWBO) Company Bio

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.

NWBO Latest News Stream

Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream

Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about NORTHWEST BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and Advent BioServices, a leading contract development and manufacturing organization (CDMO) based in the UK, jointly announce that a MIA license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K.

Yahoo | March 20, 2023

Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has no banking relationship with Silicon Valley Bank (SVB) and no funds on deposit at SVB.

Yahoo | March 11, 2023

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022, and discussion at the Meeting (which was publicly available) about achievements in 2022 and anticipated activities in 2023.

Yahoo | January 6, 2023

NWBO Stock Alert: Northwest Bio Slams Citadel Securities in New Lawsuit

Shares of Northwest Biotherapeutics (OTCMKTS:NWBO) are in focus on Thursday. NWBO stock is up about 5% on the day and it’s got investors’ attention with a lawsuit against Citadel Securities, among other firms. Here’s the skinny. The company is accusing Citadel Securities, Susquehanna and “other Wall Street firms of driving down its stock price through a series of illicit trading tactics.” It also includes Canaccord Genuity, G1 Execution Services, GTS Securities, Instinet, Lime Trading and Virtu

Yahoo | December 1, 2022

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial.

Yahoo | November 17, 2022

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo 22.41%
3-mo 18.33%
6-mo -25.58%
1-year 1.46%
3-year 89.33%
5-year 178.54%
YTD -9.50%
2022 12.07%
2021 -54.10%
2020 609.63%
2019 4.57%
2018 -12.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!